Oxford Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Oxford Asset Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$214K	Sell	3,547 -3,337	-48%	-$185K	0.11%	299
2026 Q1	$400K	Sell	6,884 -495	-7%	-$22.8K	0.16%	201
2025 Q4	$331K	Sell	7,379 -14,783	-67%	-$621K	0.12%	276
2025 Q3	$890K	Buy	22,162 +1,024	+5%	+$36.1K	0.29%	88
2025 Q2	$662K	Buy	21,138 +14,964	+242%	+$488K	0.22%	136
2025 Q1	$207K	Buy	+6,174	New	+$234K	0.09%	349
2020 Q1	–	Sell	-12,553	Closed	-$165K	–	1339
2019 Q4	$165K	Buy	+12,553	New	+$132K	﹤0.01%	1575

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Oxford Asset Management's XENE Position: Q2 2026 in Review

Oxford Asset Management reduced its Xenon Pharmaceuticals (XENE) stake by 48% in Q2 2026, selling an estimated $185K and leaving 3,547 shares worth $214K. The position accounts for 0.11% of the portfolio, ranked #299.

Oxford Asset Management first reported a position in XENE in Q4 2019 and has held it in 7 quarters since. The position peaked at $890K in Q3 2025. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Oxford Asset Management held 3,547 shares of Xenon Pharmaceuticals worth $214K as of Q2 2026.
Oxford Asset Management sold 3,337 Xenon Pharmaceuticals shares in Q2 2026, an estimated $185K.
Xenon Pharmaceuticals made up 0.11% of Oxford Asset Management's portfolio in Q2 2026, its #299 holding.
Oxford Asset Management first reported a position in Xenon Pharmaceuticals in Q4 2019 and has held it in 7 quarters since.
Oxford Asset Management's Xenon Pharmaceuticals position peaked at $890K in Q3 2025.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.